Not Tagged
novocure
['lunar ']
#asco23 lunar study of ttfields with soc showed an os benefit over soc alone with os hr 0.74, mos 13.2m vs 9.9m, 3y os rate 18% vs 7%. but no significant difference in pfs with hr 0.85, mpfs 4.8m vs 4.1m and crossing curves. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo